Rapamycin for slowing aging
The best lifespan result ever produced in mice, and a single 114-person human trial whose positive findings were confined to women on the higher dose.
The best animal result in the field
Rapamycin has the strongest lifespan evidence of any compound ever tested in mammals. In 2009 the Interventions Testing Program — a multi-site programme designed specifically to stop single labs producing unrepeatable longevity findings — reported that rapamycin extended the lifespan of genetically heterogeneous mice even when started late in life.1
That last detail is why the result mattered. Plenty of things extend mouse lifespan if you start at weaning. Very little works when begun in middle age, which is the situation an adult human is actually in.
None of that is in dispute here, and this page is not an argument that rapamycin does nothing. It is an accounting of what has been measured in people, which is a much shorter document.
The entire human trial record
One randomised placebo-controlled trial has tested rapamycin for healthy ageing in normally-ageing adults. It is called PEARL, it ran for 48 weeks, and it enrolled 114 people aged 50 to 85.2
PEARL — the only trial of its kind
Read the positive findings carefully, because how they are usually reported and what they actually are differ.
The lean-mass gain appeared in women, on the 10 mg dose only. The improvements in pain were in women, on the 10 mg dose only. The improvements in emotional wellbeing and general health were self-reported, on the 5 mg dose. Visceral fat did not move. Blood markers did not move.
These are subgroup findings and questionnaire findings from a 114-person trial. They are worth having — they are far better than nothing, which is what this field usually offers — but they are the kind of result that generates a hypothesis, not the kind that settles one.
The trial's more solid contribution is on safety: over a year, adverse events were similar across all groups.2 Weekly low-dose rapamycin in healthy adults did not produce the harm some had feared. That is genuinely useful, and it is a different claim from "it works".
What has never been measured
No trial has tested whether rapamycin extends human lifespan. None is running. The outcome is not merely unproven — it has not been the endpoint of a single randomised study.
The gap between those two rows and the mouse data at the top of this page is the whole story of longevity medicine. An exceptional animal result and a 114-person human trial are not the same evidence, and the distance between them is measured in decades and hundreds of millions of dollars — which is why it so often goes uncrossed.
Safety and unknowns
-
It is an immunosuppressant
Rapamycin is licensed to stop organ transplant rejection. That is the mechanism, not a side effect of it. Weekly low dosing is intended to hit a different target than daily transplant dosing, but the drug's primary pharmacological action is suppression of an immune pathway.
-
Known adverse effects at therapeutic doses
Mouth ulcers, raised blood lipids, impaired wound healing, glucose intolerance and increased infection risk. PEARL found adverse events comparable to placebo at weekly low doses over one year, which does not extend to higher or more frequent regimens.
-
Longest evidence in healthy people
48 weeks, in 114 people. Nothing published speaks to years of use in a healthy adult.
-
What was actually taken
PEARL used compounded rapamycin. Compounded preparations are not subject to the same manufacturing verification as the licensed product, so even this single trial is not straightforwardly a trial of the drug as dispensed by a pharmacy.
How the grade was reached
Evidence strength — Emerging, criteria checked
Animal evidence does not lift a human claim under our scale, however good it is. The last row is there because leaving it out would misrepresent why this compound is taken seriously — but it is not what the dots measure.
Bottom line
Rapamycin is the most interesting compound in this field and the one with the least human evidence relative to its reputation. The mouse data is exceptional and repeatable. The human data is a single 114-person trial whose positive findings were confined to women on the higher dose, or to questionnaires.
What that trial did establish reasonably well is that a year of weekly low-dose rapamycin did not visibly harm healthy adults. That is a real contribution and it is not the same as benefit.
It is a prescription immunosuppressant. Nobody has tested whether it makes a person live longer, and until somebody does, the honest mark is two dots.
Sources
- Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392–395. PMID 19587680. pubmed.ncbi.nlm.nih.gov/19587680
- Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging. 2025. Randomised, double-blind, placebo-controlled; 114 adults aged 50–85; 48 weeks. pmc.ncbi.nlm.nih.gov/PMC12074816
- Safety and efficacy of rapamycin on healthspan metrics after one year: PEARL trial results. Preprint of the above, August 2024. medrxiv.org
- Aging (journal). Low-dose rapamycin improves muscle mass and well-being in aging adults. Publisher summary of the PEARL results, including the subgroup restrictions. aging-us.com
- Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale. 2025. PMID 39951177. The companion-dog trial often cited alongside the human work. pubmed.ncbi.nlm.nih.gov/39951177
- A masked, placebo-controlled, randomized clinical trial evaluating safety and the effect of low-dose rapamycin on cardiac function in healthy dogs. 2023. PMID 37275618. pubmed.ncbi.nlm.nih.gov/37275618
